Our data demonstrated that expression levels of p53 mRNA and protein were dramatically decreased upon AR-42 treatment, suggesting that AR-42 could decrease deleterious effects of mutant p53 in pancreatic cancer cells (Fig 4A and 4B), and such inhibitory effect was greater than other pan-HDAC inhibitors, TSA and SAHA (S4 Fig). The gene discussed is HDAC9; the disease is pancreatic neoplasm.